Abound Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-104
Closed -$2.75K – 1378
2026
Q1
$2.75K Hold
104
– – ﹤0.01% 854
2025
Q4
$3.01K Buy
+104
New +$3.12K ﹤0.01% 783
2024
Q4
– Sell
-2
Closed -$52 – 1233
2024
Q3
$52 Buy
+2
New +$51 ﹤0.01% 1293

Other funds holding ARKG

Abound Wealth Management's ARKG Position: Q2 2026 in Review

Abound Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2026, closing a stake of 104 shares — an estimated $2.75K sold.

Abound Wealth Management first reported a position in ARKG in Q3 2024 and held it in 3 quarters. The position peaked at $3.01K in Q4 2025. 274 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Abound Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q2 2026 after selling out during the quarter.
  • Abound Wealth Management sold 104 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $2.75K.
  • Abound Wealth Management first reported a position in ARK Genomic Revolution ETF in Q3 2024 and held it in 3 quarters.
  • Abound Wealth Management's ARK Genomic Revolution ETF position peaked at $3.01K in Q4 2025.
  • 274 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.